UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) – January 10, 2020
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||
(Address of principal executive offices) | (Zip Code) | |||||
Registrant’s telephone number, including area code: 610 -594-2900
Not Applicable |
(Former name or address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 1.01. Entry into a Material Definitive Agreement.
On January 10, 2020, West Pharmaceutical Services, Inc. (the “Company”) entered into a global master supply agreement (the “Agreement”) with ExxonMobil Chemical Company (“EMCC”). The Agreement is effective for the period January 1, 2019 through December 31, 2023.
Under the Agreement, EMCC and certain of its subsidiaries have agreed to supply certain identified Exxon® (Exxon is a registered trademark of ExxonMobil Corporation) butyl polymers to the Company and certain of its subsidiaries and affiliates. The EMCC products are used as a principal raw material in a broad range of the Company’s polymer-based pharmaceutical packaging products.
The summary of the terms is qualified in its entirety by reference to the Agreement, which is attached hereto as Exhibit 10.1 and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) | Exhibit No. | Description |
10.1+ | Global Master Supply Agreement, entered into on January 10, 2020, and effective from January 1, 2019 through December 31, 2023, between West Pharmaceutical Services, Inc. and ExxonMobil Chemical Company. | |
104 | The cover page from the Company’s Current Report on Form 8-K, dated January 10, 2020, formatted in Inline XBRL. | |
+ Portions of this exhibit (indicated therein by asterisks) have been omitted for confidential treatment.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
WEST PHARMACEUTICAL SERVICES, INC. | |
/s/ George L. Miller | |
George L. Miller | |
Senior Vice President, General Counsel and Corporate Secretary | |
January 16, 2020 | |
3
EXHIBIT INDEX
Exhibit No. | Description | |
10.1+ | ||
104 | The cover page from the Company’s Current Report on Form 8-K, dated January 10, 2020, formatted in Inline XBRL. | |
4